harmalol has been researched along with MPTP Neurotoxicity Syndrome in 1 studies
harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure
harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CS | 1 |
| Han, ES | 1 |
| Jang, YY | 1 |
| Han, JH | 1 |
| Ha, HW | 1 |
| Kim, DE | 1 |
1 other study available for harmalol and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Electron Transport; Free Rad | 2000 |